PHILADELPHIA, July 31, 2013 — Iroko Pharmaceuticals Inc., a global specialty pharmaceutical company dedicated to scientific advancements in analgesia, today announced that it has decided not to pursue its initial public offering (IPO). The company intends to withdraw its registration statement on Form F-1 filed with the Securities and Exchange Commission.
“While we have received significant interest from the investment community in our IPO, we have determined that the timing of this offering may not be optimal and in the best interest of the company,” said John Vavricka, President and CEO of Iroko Pharmaceuticals. “This is a critical period for Iroko as we prepare to bring to market our first product candidate in the coming months, and as an organization we need to focus on this important milestone. Due to the continuing support of our existing shareholders, we remain well poised to execute on both our product development plans and business strategies.”
Meredith Jarblum for Iroko Pharmaceuticals Inc., 212-798-9775
Kate de Santis, Iroko Pharmaceuticals Inc., 267-546-1682